Evaluation of new 99mTc(CO)3 + radiolabeled glycylglycine In Vivo

Simple item page
dc.contributor.authorŞenışık A.M.
dc.contributor.authorİçhedef Ç.
dc.contributor.authorKılçar A.Y.
dc.contributor.authorUçar E.
dc.contributor.authorArı K.
dc.contributor.authorParlak Y.
dc.contributor.authorBilgin E.S.
dc.contributor.authorTeksöz S.
dc.date.accessioned2024-07-22T08:08:58Z
dc.date.available2024-07-22T08:08:58Z
dc.date.issued2019
dc.description.abstractBackground: Peptide-based agents are used in molecular imaging due to their unique properties, such as rapid clearance from the circulation, high affinity and target selectivity. Many of the radiolabeled peptides have been clinically experienced with diagnostic accuracy. The aim of this study was to investigate in vivo biological behavior of [99mTc(CO)3(H2O)3]+ radiolabeled glycylglycine (GlyGly). Methods: Glycylglycine was radiolabeled with a high radiolabeling yield of 94.69±2%, and quality control of the radiolabeling process was performed by thin layer radiochromatography (TLRC) and High-Performance Liquid Radiochromatography (HPLRC). Lipophilicity study for radiolabeled complex (99mTc(CO)3-Gly-Gly) was carried out using solvent extraction. The in vivo evaluation was performed by both biodistribution and SPECT imaging. Results: The high radiolabelling yield of 99mTc(CO)3-GlyGly was obtained and verified by TLRC and HPLRC as well. According to the in vivo results, SPECT images and biodistribution data are in good accordance. The excretion route from the body was both hepatobiliary and renal. Conclusion: This study shows that 99mTc(CO)3-GlyGly has the potential to be used as a peptide-based imaging agent. Further studies, 99mTc(CO)3-GlyGly can be performed on tumor-bearing animals. © 2019 Bentham Science Publishers.
dc.identifier.DOI-ID10.2174/1871520619666190404154723
dc.identifier.issn18715206
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14575
dc.language.isoEnglish
dc.publisherBentham Science Publishers
dc.subjectAnimals
dc.subjectCarbon Monoxide
dc.subjectGlycylglycine
dc.subjectRadiopharmaceuticals
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectTechnetium
dc.subjectTissue Distribution
dc.subjectglycylglycine
dc.subjectradiopharmaceutical agent
dc.subjecttc 99m tricarbonyl complex glycylglycine
dc.subjecttechnetium 99m
dc.subjectunclassified drug
dc.subjectcarbon monoxide
dc.subjectglycylglycine
dc.subjectradiopharmaceutical agent
dc.subjecttechnetium
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectArticle
dc.subjectchromatography by mobile phase
dc.subjectcontrolled study
dc.subjectflow rate
dc.subjecthigh performance liquid radiochromatography
dc.subjectisotope labeling
dc.subjectlipophilicity
dc.subjectmale
dc.subjectnonhuman
dc.subjectquality control
dc.subjectradiochemistry
dc.subjectradiochromatography
dc.subjectradioisotope distribution
dc.subjectrat
dc.subjectretention time
dc.subjectsingle photon emission computed tomography
dc.subjectsolvent extraction
dc.subjecttemperature
dc.subjectthin layer radiochromatography
dc.subjectanimal
dc.subjectchemistry
dc.subjecttissue distribution
dc.subjectWistar rat
dc.titleEvaluation of new 99mTc(CO)3 + radiolabeled glycylglycine In Vivo
dc.typeArticle

Files

Collections

Scopus Koleksiyonu